RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaPhase 1

Registered title, quoted from ClinicalTrials.gov

JMT106 Injection in the Treatment of Advanced Solid Tumors

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07275073, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 9

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (9 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed advanced solid tumor.

    Inclusion criterion 2

  3. NYHA class ≥II or LVEF <50%;

    Exclusion criterion 22

  4. Previous treatment with anti-GPC3 therapy.

    Exclusion criterion 1

    Grade ≥3 immune-related adverse events (irAEs, per CTCAE 5.0) from prior immunotherapy.

    Exclusion criterion 6

  5. ECOG performance status of 0-1.

    Inclusion criterion 5

  6. Absolute neutrophil count (ANC) ≥1.5×10⁹/L;

    Inclusion criterion 8

    Platelets (PLT) ≥90×10⁹/L;

    Inclusion criterion 9

    Hemoglobin (Hb) ≥90 g/L;

    Inclusion criterion 10

    Total bilirubin (TBIL) ≤1.5×ULN (≤3×ULN for liver metastases or hepatocellular carcinoma);

    Inclusion criterion 11

    Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN (≤5×ULN for liver metastases or hepatocellular carcinoma);

    Inclusion criterion 12

    Creatinine clearance (Ccr) >50 mL/min (calculated by Cockcroft-Gault formula);

    Inclusion criterion 13

    Activated partial thromboplastin time (APTT) ≤1.5×ULN; INR ≤1.5×ULN.

    Inclusion criterion 14

  7. At least one measurable lesion according to RECIST 1.1 criteria.

    Inclusion criterion 4

  8. Active bacterial, fungal, or viral infection requiring IV treatment within 14 days before randomization (prophylactic therapy allowed if no active infection symptoms); patients with viral hepatitis are allowed to receive antiviral treatment.

    Exclusion criterion 11

    Immunodeficiency, including HIV-positive status.

    Exclusion criterion 14

    HBsAg-positive or HBcAb-positive with HBV-DNA >2000 IU/mL; HCV antibody-positive with HCV-RNA positivity.

    Exclusion criterion 15

    History of tuberculosis treatment within 2 years before the first dose.

    Exclusion criterion 16

    Other active malignancies within 2 years (except cured localized tumors, e.g., basal cell carcinoma, squamous cell carcinoma, superficial bladder cancer, in situ prostate/cervical/breast cancer).

    Exclusion criterion 25

  9. Fertile participants (male and female) must agree to use reliable contraception (hormonal, barrier, or abstinence) with their partners during the trial and for at least 180 days after the last dose. Female participants of childbearing potential must have a negative blood pregnancy test within 7 days before enrollment.

    Inclusion criterion 15

    Pregnancy or lactation.

    Exclusion criterion 27

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07275073, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age ≥18 years.
  • Histologically or cytologically confirmed advanced solid tumor.
  • Failure of at least one line of standard therapy, or no standard treatment available, or intolerant to standard treatment at the current stage.
  • At least one measurable lesion according to RECIST 1.1 criteria.
  • ECOG performance status of 0-1.
  • Expected survival ≥3 months.
  • Sufficient organ function, with laboratory tests meeting the following criteria (no blood transfusion or hematopoietic growth factor treatment within 14 days):
  • Absolute neutrophil count (ANC) ≥1.5×10⁹/L;
  • Platelets (PLT) ≥90×10⁹/L;
  • Hemoglobin (Hb) ≥90 g/L;
  • Total bilirubin (TBIL) ≤1.5×ULN (≤3×ULN for liver metastases or hepatocellular carcinoma);
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN (≤5×ULN for liver metastases or hepatocellular carcinoma);
  • Creatinine clearance (Ccr) >50 mL/min (calculated by Cockcroft-Gault formula);
  • Activated partial thromboplastin time (APTT) ≤1.5×ULN; INR ≤1.5×ULN.
  • Fertile participants (male and female) must agree to use reliable contraception (hormonal, barrier, or abstinence) with their partners during the trial and for at least 180 days after the last dose. Female participants of childbearing potential must have a negative blood pregnancy test within 7 days before enrollment.
  • Understand and voluntarily sign the informed consent form (ICF).

Exclusion Criteria:

  • Previous treatment with anti-GPC3 therapy.
  • Presence of spinal cord compression or clinically active central nervous system metastases (untreated or symptomatic metastases, or those requiring corticosteroids/anticonvulsants for symptom control), or carcinomatous meningitis. Patients with previously treated brain metastases (e.g., whole-brain radiotherapy or stereotactic brain radiotherapy) may be enrolled if clinically stable for ≥4 weeks with no imaging evidence of progressive brain metastases.
  • Long-term immunosuppressive therapy (e.g., cyclosporine) or daily systemic steroid therapy (e.g., >20 mg prednisone or equivalent), excluding those using nasal spray, inhaled, or other topical glucocorticoid therapies.
  • Adverse reactions from prior antitumor therapy not recovered to CTCAE 5.0 Grade ≤1 (excluding toxicities deemed non-risky by the investigator, e.g., alopecia).
  • Any antitumor therapy (chemotherapy, targeted therapy, immunotherapy, etc.) or investigational intervention within 4 weeks or 5 half-lives (whichever is shorter) before the first dose, or traditional Chinese medicine with antitumor indications within 14 days prior.
  • Grade ≥3 immune-related adverse events (irAEs, per CTCAE 5.0) from prior immunotherapy.
  • Concurrent participation in another interventional clinical trial (observational trials or follow-up phases allowed).
  • Major surgery within 28 days before the first dose or planned tumor resection during the study.
  • Significant bleeding tendency within 4 weeks before the first dose, or high-risk conditions (e.g., gastrointestinal hemorrhage, severe hemoptysis) per investigator judgment; hereditary bleeding disorders.
  • Known severe allergy to the study drug or its excipients.
  • Active bacterial, fungal, or viral infection requiring IV treatment within 14 days before randomization (prophylactic therapy allowed if no active infection symptoms); patients with viral hepatitis are allowed to receive antiviral treatment.
  • Uncontrolled effusions (pleural, peritoneal, pericardial) requiring frequent drainage or intervention within 14 days before the first dose (excluding cytologic evaluation of effusions).
  • History of allogeneic organ or hematopoietic stem cell transplantation.
  • Immunodeficiency, including HIV-positive status.
  • HBsAg-positive or HBcAb-positive with HBV-DNA >2000 IU/mL; HCV antibody-positive with HCV-RNA positivity.
  • History of tuberculosis treatment within 2 years before the first dose.
  • Interstitial lung disease or severe pulmonary dysfunction.
  • History of inflammatory bowel disease or chronic diarrhea.
  • Severe cardiovascular/cerebrovascular disease, including:
  • Severe arrhythmias/conduction abnormalities (e.g., ventricular arrhythmias requiring intervention, AV block grade II-III);
  • Acute coronary syndrome, congestive heart failure, stroke, or other Grade ≥3 cardiovascular events within 6 months before the first dose;
  • NYHA class ≥II or LVEF <50%;
  • Long QTc syndrome or QTc >480 ms (Fridericia formula), or concomitant use of QTc-prolonging drugs;
  • Uncontrolled hypertension (systolic BP ≥160 mmHg and/or diastolic BP ≥100 mmHg at screening).
  • Other active malignancies within 2 years (except cured localized tumors, e.g., basal cell carcinoma, squamous cell carcinoma, superficial bladder cancer, in situ prostate/cervical/breast cancer).
  • Live vaccination within 28 days before the first dose (inactivated vaccines, e.g., seasonal flu vaccine, allowed).
  • Pregnancy or lactation.
  • Other conditions deemed unsuitable by the investigator (e.g., depression history/current treatment, psychiatric disorders affecting compliance, main portal vein tumor thrombus).

Quoted from ClinicalTrials.gov, NCT07275073, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07275073, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07275073